Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues. …
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
November 6, 2023 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle
February 17, 2026 - - Latest News -
Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines
February 16, 2026 - - Latest News -
Director pay rises across ASX healthcare sector, but gender balance remains uneven
February 16, 2026 - - Latest News -
Life sciences sector unites to advance women’s leadership at landmark 2026 events
February 16, 2026 - - Latest News -
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 - - Australian Biotech -
Medibank funding expansion signals momentum for Emyria’s mental health model
February 16, 2026 - - Latest News -
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 - - Latest News